Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
Public ClinicalTrials.gov record NCT00772538. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (5 mcg/Day) Over 48 Weeks as add-on Controller Therapy on Top of Usual Care in Patients With Severe Persistent Asthma
Study identification
- NCT ID
- NCT00772538
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 459 participants
Conditions and interventions
Conditions
Interventions
- placebo Drug
- tiotropium 5mcg/day Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2008
- Primary completion
- Jun 30, 2011
- Completion
- Not listed
- Last update posted
- Aug 17, 2014
Started 2008
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.416.01007 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 205.416.01012 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.416.01018 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 205.416.01016 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 205.416.01008 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.416.01004 Boehringer Ingelheim Investigational Site | Walnut Creek | California | — | — |
| 205.416.01010 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 205.416.01023 Boehringer Ingelheim Investigational Site | Tallahassee | Florida | — | — |
| 205.416.01002 Boehringer Ingelheim Investigational Site | Elk Grove Village | Illinois | — | — |
| 205.416.01003 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 205.416.01014 Boehringer Ingelheim Investigational Site | Wheaton | Maryland | — | — |
| 205.416.01025 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 205.416.01022 Boehringer Ingelheim Investigational Site | Columbia | Missouri | — | — |
| 205.416.01021 Boehringer Ingelheim Investigational Site | Boys Town | Nebraska | — | — |
| 205.416.01011 Boehringer Ingelheim Investigational Site | Cherry Hill | New Jersey | — | — |
| 205.416.01001 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.416.01024 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.416.01017 Boehringer Ingelheim Investigational Site | Lake Oswego | Oregon | — | — |
| 205.416.01019 Boehringer Ingelheim Investigational Site | El Paso | Texas | — | — |
| 205.416.01009 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00772538, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2014 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00772538 live on ClinicalTrials.gov.